What is Zacks Research’s Forecast for Revvity Q2 Earnings?

Revvity Inc. (NYSE:RVTY) – Stock analysts at Zacks Research cut their Q2 2028 earnings per share (EPS) estimates for shares of Revvity in a research report issued to clients and investors on Thursday, June 25th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.64 per share for the quarter, down from their previous forecast of $1.66. The consensus estimate for Revvity’s current full-year earnings is $5.25 per share.

RVTY has been the topic of several other reports. Wolfe Research started coverage on shares of Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. TD Cowen lifted their price objective on shares of Revvity from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Sanford C. Bernstein began coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 price objective for the company. Barclays increased their target price on shares of Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $108.33.

Revvity Stock Up 1.4%

RVTY opened at $112.80 on Thursday. The stock has a fifty day moving average of $98.62 and a 200-day moving average of $97.94. The company has a market capitalization of $12.58 billion, a P/E ratio of 53.97, a P/E/G ratio of 2.43 and a beta of 1.09. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $118.30. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $711.12 million for the quarter, compared to analyst estimates of $704.07 million. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 EPS. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Ascentis Independent Advisors acquired a new position in Revvity in the first quarter valued at about $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity during the second quarter worth about $32,000. Cromwell Holdings LLC grew its stake in Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after buying an additional 198 shares in the last quarter. MUFG Securities EMEA plc bought a new position in Revvity in the 2nd quarter valued at about $34,000. Finally, Headlands Technologies LLC bought a new position in Revvity in the 2nd quarter valued at about $49,000. Institutional investors own 86.65% of the company’s stock.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, July 17th. Revvity’s dividend payout ratio is 13.40%.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.